{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:38:08Z","timestamp":1792125488080,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T00:00:00Z","timestamp":1534723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T00:00:00Z","timestamp":1534723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biomed Eng"],"DOI":"10.1038\/s41551-018-0279-x","type":"journal-article","created":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T13:24:32Z","timestamp":1534166672000},"page":"822-830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs"],"prefix":"10.1038","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5848-7366","authenticated-orcid":false,"given":"Matthew R.","family":"Golder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannik N.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail V.","family":"Shipitsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrukh","family":"Vohidov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung V.-T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah C.","family":"Ehrlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Jin","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavatarini","family":"Vangamudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriakos D.","family":"Economides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison M.","family":"Neenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Ackley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Baddour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattanathan","family":"Paramasivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha W.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Saucier-Sawyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Kopesky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald E.","family":"Chickering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Blume-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9157-6491","authenticated-orcid":false,"given":"Jeremiah A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,20]]},"reference":[{"key":"279_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-014-0145-y","volume":"12","author":"AA Mokdad","year":"2014","unstructured":"Mokdad, A. A. et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Medicine 12, 145 (2014).","journal-title":"BMC Medicine"},{"key":"279_CR2","doi-asserted-by":"publisher","first-page":"167sr161","DOI":"10.1126\/scitranslmed.3004700","volume":"5","author":"SL Friedman","year":"2013","unstructured":"Friedman, S. L., Sheppard, D., Duffield, J. S. & Violette, S. Therapy for fibrotic diseases: nearing the starting line. Sci. Transl. Med. 5, 167sr161 (2013).","journal-title":"Sci. Transl. Med."},{"key":"279_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1478-3231.2011.02517.x","volume":"32","author":"KM Fleming","year":"2012","unstructured":"Fleming, K. M., Aithal, G. P., Card, T. R. & West, J. All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study. Liver Int. 32, 79\u201384 (2012).","journal-title":"Liver Int."},{"key":"279_CR4","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","volume":"62 (Suppl. 1)","author":"C Trautwein","year":"2015","unstructured":"Trautwein, C., Friedman, S. L., Schuppan, D. & Pinzani, M. Hepatic fibrosis: concept to treatment. J. Hepatol. 62 (Suppl. 1), S15\u2013S24 (2015).","journal-title":"J. Hepatol."},{"key":"279_CR5","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/gutjnl-2014-306842","volume":"64","author":"YA Lee","year":"2015","unstructured":"Lee, Y. A., Wallace, M. C. & Friedman, S. L. Pathobiology of liver fibrosis: a translational success story. Gut 64, 830 (2015).","journal-title":"Gut"},{"key":"279_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.2277","volume":"214","author":"TA Wynn","year":"2008","unstructured":"Wynn, T. A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199\u2013210 (2008).","journal-title":"J. Pathol."},{"key":"279_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1172\/JCI24282","volume":"115","author":"R Bataller","year":"2005","unstructured":"Bataller, R. & Brenner, D. A. Liver fibrosis. J. Clin. Investig. 115, 209\u2013218 (2005).","journal-title":"J. Clin. Investig."},{"key":"279_CR8","doi-asserted-by":"publisher","first-page":"942","DOI":"10.3748\/wjg.15.942","volume":"15","author":"EF Georgescu","year":"2009","unstructured":"Georgescu, E. F., Ionescu, R., Niculescu, M., Mogoanta, L. & Vancica, L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J. Gastroenterol. 15, 942\u2013954 (2009).","journal-title":"World J. Gastroenterol."},{"key":"279_CR9","unstructured":"Micardis (Boehringer-Ingelheim, 2014); https:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Micardis%20Tabs\/MICARDIS20-40-80mg.PDF"},{"key":"279_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3516","volume":"4","author":"VP Chauhan","year":"2013","unstructured":"Chauhan, V. P. et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun. 4, 2516 (2013).","journal-title":"Nat. Commun."},{"key":"279_CR11","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1056\/NEJMra1504367","volume":"375","author":"PS Ge","year":"2016","unstructured":"Ge, P. S. & Runyon, B. A. Treatment of patients with cirrhosis. N. Engl. J. Med. 375, 767\u2013777 (2016).","journal-title":"N. Engl. J. Med."},{"key":"279_CR12","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1021\/cm2031569","volume":"24","author":"NL Hamidreza","year":"2012","unstructured":"Hamidreza, N. L. Polymeric conjugates for drug delivery. Chem. Mater. 24, 840\u2013853 (2012).","journal-title":"Chem. Mater."},{"key":"279_CR13","doi-asserted-by":"publisher","first-page":"11476","DOI":"10.1021\/acs.chemrev.7b00194","volume":"117","author":"C Kinnear","year":"2017","unstructured":"Kinnear, C., Moore, T. L., Rodriguez-lorenzo, L., Rothen-Rutishauser, B. & Petri-fink, A. Form follows function: nanoparticle shape and its implications for nanomedicine. Chem. Rev. 117, 11476\u201311521 (2017).","journal-title":"Chem. Rev."},{"key":"279_CR14","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco, E., Shen, H. & Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33, 941\u2013951 (2015).","journal-title":"Nat. Biotechnol."},{"key":"279_CR15","doi-asserted-by":"publisher","first-page":"7242","DOI":"10.3748\/wjg.v20.i23.7242","volume":"20","author":"L Giannitrapani","year":"2014","unstructured":"Giannitrapani, L., Soresi, M., Bond\u00ec, M. L., Montalto, G. & Cervello, M. Nanotechnology applications for the therapy of liver fibrosis. World J. Gastroenterol. 20, 7242\u20137251 (2014).","journal-title":"World J. Gastroenterol."},{"key":"279_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nature01451","volume":"422","author":"SD Conner","year":"2003","unstructured":"Conner, S. D. & Schmid, S. L. Regulated portals of entry into the cell. Nature 422, 37\u201344 (2003).","journal-title":"Nature"},{"key":"279_CR17","first-page":"364","volume":"3","author":"M Bartneck","year":"2014","unstructured":"Bartneck, M., Warzecha, K. T. & Tacke, F. Therapeutic targeting of liver inflammation and fibrosis by nanomedicine. Hepatobiliary Surg. Nutr. 3, 364\u2013376 (2014).","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"279_CR18","doi-asserted-by":"publisher","first-page":"17028","DOI":"10.1039\/C3RA47370H","volume":"4","author":"Z Ahmad","year":"2014","unstructured":"Ahmad, Z., Shah, A., Siddiq, M. & Kraatz, H. B. Polymeric micelles as drug delivery vehicles. RSC Adv. 4, 17028\u201317028 (2014).","journal-title":"RSC Adv."},{"issue":"48","key":"279_CR19","doi-asserted-by":"publisher","first-page":"15170","DOI":"10.1002\/anie.201709002","volume":"56","author":"Jean-Christophe Leroux","year":"2017","unstructured":"Leroux, J.-C. Too much complexity, not enough reproducibility? Angew. Chem. Int. Ed. 56, 15170\u201315171 (2017).","journal-title":"Angewandte Chemie International Edition"},{"key":"279_CR20","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","volume":"33","author":"D Bobo","year":"2016","unstructured":"Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J. & Corrie, S. R. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm. Res. 33, 2373\u20132387 (2016).","journal-title":"Pharm. Res."},{"key":"279_CR21","doi-asserted-by":"publisher","first-page":"10326","DOI":"10.1021\/ma1021506","volume":"43","author":"JA Johnson","year":"2010","unstructured":"Johnson, J. A. et al. Drug-loaded, bivalent-bottle-brush polymers by graft-through ROMP. Macromolecules 43, 10326\u201310335 (2010).","journal-title":"Macromolecules"},{"key":"279_CR22","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1021\/ja108441d","volume":"133","author":"JA Johnson","year":"2011","unstructured":"Johnson, J. A. et al. Core-clickable PEG-branch-azide bivalent-bottle-brush polymers by ROMP: grafting-through and clicking-to. J. Am. Chem. Soc. 133, 559\u2013566 (2011).","journal-title":"J. Am. Chem. Soc."},{"key":"279_CR23","doi-asserted-by":"publisher","first-page":"16337","DOI":"10.1021\/ja3067176","volume":"134","author":"J Liu","year":"2012","unstructured":"Liu, J. et al. \u2018Brush-first\u2019 method for the parallel synthesis of photocleavable, nitroxide-labeled poly(ethylene glycol) star polymers. J. Am. Chem. Soc. 134, 16337\u201316344 (2012).","journal-title":"J. Am. Chem. Soc."},{"key":"279_CR24","doi-asserted-by":"publisher","first-page":"5896","DOI":"10.1021\/ja502011g","volume":"136","author":"L Liao","year":"2014","unstructured":"Liao, L. et al. A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin. J. Am. Chem. Soc. 136, 5896\u20135899 (2014).","journal-title":"J. Am. Chem. Soc."},{"key":"279_CR25","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1021\/mz5004097","volume":"3","author":"AX Gao","year":"2014","unstructured":"Gao, A. X., Liao, L. & Johnson, J. A. Synthesis of acid-labile PEG and PEG\u2013doxorubicin-conjugate nanoparticles via brush-first ROMP. ACS Macro Lett. 3, 854\u2013857 (2014).","journal-title":"ACS Macro Lett."},{"key":"279_CR26","doi-asserted-by":"publisher","first-page":"12494","DOI":"10.1021\/jacs.6b06321","volume":"138","author":"JC Barnes","year":"2016","unstructured":"Barnes, J. C. et al. Using an RNAi signature assay to guide the design of three-drug-conjugated nanoparticles with validated mechanisms, in vivo efficacy, and low toxicity. J. Am. Chem. Soc. 138, 12494\u201312501 (2016).","journal-title":"J. Am. Chem. Soc."},{"key":"279_CR27","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/jps.20542","volume":"95","author":"BM Liederer","year":"2006","unstructured":"Liederer, B. M. & Borchardt, R. T. Enzymes involved in the bioconversion of ester-based prodrugs. J. Pharm. Sci. 95, 1177\u20131195 (2006).","journal-title":"J. Pharm. Sci."},{"key":"279_CR28","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nnano.2011.166","volume":"6","author":"H Cabral","year":"2011","unstructured":"Cabral, H. et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotech. 6, 815\u2013823 (2011).","journal-title":"Nat. Nanotech."},{"key":"279_CR29","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"RK Jain","year":"2014","unstructured":"Jain, R. K. Antiangiogenesis strategies revisited: Ffrom starving tumors to alleviating hypoxia. Cancer Cell 26, 605\u2013622 (2014).","journal-title":"Cancer Cell"},{"key":"279_CR30","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.drudis.2014.06.002","volume":"19","author":"A Baumann","year":"2014","unstructured":"Baumann, A., Tuerck, D., Prabhu, S., Dickmann, L. & Sims, J. Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis?. Drug Discov. Today 19, 1623\u20131631 (2014).","journal-title":"Drug Discov. Today"},{"key":"279_CR31","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1177\/0192623315591171","volume":"43","author":"IA Ivens","year":"2015","unstructured":"Ivens, I. A. et al. PEGylated biopharmaceuticals. Toxicol. Pathol. 43, 959\u2013983 (2015).","journal-title":"Toxicol. Pathol."},{"key":"279_CR32","unstructured":"M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (FDA, 2010); http:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm073246.pdf"},{"key":"279_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00795-013-0016-1","volume":"46","author":"M Fujii","year":"2013","unstructured":"Fujii, M. et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med. Mol. Morphol. 46, 141\u2013152 (2013).","journal-title":"Med. Mol. Morphol."},{"key":"279_CR34","first-page":"4849","volume":"34","author":"K Takaura","year":"2014","unstructured":"Takaura, K. et al. Characterization of non-alcoholic steatohepatitis-derived hepatocellular carcinoma as a human stratification model in mice. Anticancer Res. 34, 4849\u20134855 (2014).","journal-title":"Anticancer Res."},{"key":"279_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm. 7, 27\u201331 (2016).","journal-title":"J. Basic Clin. Pharm."}],"updated-by":[{"DOI":"10.1038\/s41551-018-0299-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T00:00:00Z","timestamp":1535932800000}}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-018-0279-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-018-0279-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-018-0279-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T23:28:35Z","timestamp":1671578915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-018-0279-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,20]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11]]}},"alternative-id":["279"],"URL":"https:\/\/doi.org\/10.1038\/s41551-018-0279-x","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41551-018-0299-6","asserted-by":"object"}]},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,20]]},"assertion":[{"value":"14 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of this Article originally published, the author Peter Blume-Jensen was not denoted as a corresponding author; this has now been amended and the author\u2019s email address has been added. The \u2018Correspondence and requests for materials\u2019 statement was similarly affected and has now been updated with the author\u2019s initials \u2018P.B-J.\u2019","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.L., J.N.A., M.V.S., S.J.H., B.V., K.D.E., A.M.N., J.C.A., J.B., S.P., S.W.B., E.J.H., J.K.S.-S., P.W.K., D.E.C. and P.B.-J. are former employees and shareholders of XTuit Pharmaceuticals. P.B.-J. is President and Founder of Acrivon Therapeutics. J.A.J. is a Co-Founder of Acrivon Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}